Search for data related to genes or regions
+
97 Study Datasets reported containing markers in gene or region ADAM19 (no 5′ and no 3′ flanks) with -log p ≥ 0
Pages: 1 2
No data sets (in No Phenotypes) added to Browser
Phenotype tested in Study Phenotype ontology annotation Total p-values in Study StudyAdd data sets to Browser Related Study data
Kuru (HGVPM3053)
  • Kuru
785,985 GWAS of prion diseases (HGVST1013)
Log10 fibrinogen (HGVPM570)
  • Fibrinogen
959,443 GWAS of log10 fibrinogen in a British population (HGVST314)
Log10 glycosylated haemoglobin (HGVPM569)
  • Glycated Hemoglobin A
959,443 GWAS of log10 glycosylated haemoglobin in a British population (HGVST313)
Log10 serum total immunoglobulin E concentration (HGVPM562)
  • Immunoglobulin E
959,443 GWAS of log10 serum total immunoglobulin E concentration in a British population (HGVST306)
Lung function (FEV1/FVC) (HGVPM5765)
  • Forced Expiratory Volume
56 GWAS of Lung function (HGVST2907)
Lung function (FEV1/FVC) (HGVPM6817)
  • Respiratory Function Tests
719 GWAS of Various traits (HGVST3468)
Lung function (FEV1/FVC) (HGVPM7098)
  • Respiratory Function Tests
162 GWAS of Lung function (HGVST3580)
Mean platelet volume (HGVPM11618)
  • Mean Platelet Volume
829 GWAS of Hematological traits (HGVST4484)
Medication use (adrenergics, inhalants) (HGVPM13047)
  • Adrenergic Agents
51 GWAS of Various traits (HGVST4815)
Medication use (adrenergics, inhalants) (HGVPM7286)
  • Adrenergic Agents
56 GWAS of Medication use (HGVST3651)
Monoclonal gammopathy of undetermined significance (HGVPM3729)
  • Monoclonal Gammopathy of Undetermined Significance
4,999 GWAS of Monoclonal gammopathy of unknown significance (MGUS) (HGVST1853)
Narcolepsy (HGVPM165)
  • Narcolepsy
1,223,685 GWAS of narcolepsy in a Japanese population (HGVST115)
Nephropathy (HGVPM994)
  • Glomerulonephritis, IGA
286,197 GWAS of nephropathy (HGVST558)
Neuropathic pain-like symptoms (HGVPM3681)
  • Neuralgia
5,492 GWAS of Neuropathic pain-like symptoms (HGVST1846)
Neutrophil count (HGVPM13450)
  • Neutrophils
522 GWAS of Blood traits (HGVST4908)
Neutrophil percentage of white cells (HGVPM13469)
  • Neutrophils
457 GWAS of Blood traits (HGVST4908)
Nonatopic asthma (HGVPM10337)
  • Asthma
108 GWAS of Obesity and asthma (HGVST4318)
Nose profile (HGVPM3666)
  • Nose
10,155 GWAS of Facial features (HGVST1841)
Parkinson's disease (HGVPM3)
  • Parkinson Disease
1,187,523 GWAS of Parkinson's disease (HGVST6)
Parkinson's disease (HGVPM126)
  • Parkinson Disease
192,227 GWAS of Parkinson's disease (HGVST83)
Partial epilepsies (HGVPM929)
  • Epilepsies, Partial
1,056,072 GWAS of partial epilepsies (HGVST522)
Peak expiratory flow (HGVPM7101)
  • Peak Expiratory Flow Rate
133 GWAS of Lung function (HGVST3580)
Proinsulin levels (HGVPM1538)
  • Proinsulin
2,496,050 GWAS of proinsulin levels (HGVST907)
Prostate cancer (HGVPM1)
  • Prostatic Neoplasms
4,170,229 GWAS of prostate cancer (HGVST1)
Psoriasis (HGVPM1532)
  • Psoriasis
440,151 GWAS of psoriasis (HGVST902)
Pulmonary function (FEV1) (HGVPM1597)
  • Respiratory Function Tests
2,419,132 GWAS of pulmonary function (HGVST946)
Pulmonary function (FEV1/FVC) (HGVPM1596)
  • Respiratory Function Tests
2,419,132 GWAS of pulmonary function (HGVST946)
Pulmonary function (interaction) (FEV1/FVC, Ever-smoking) (HGVPM2454)
  • Forced Expiratory Volume
  • Vital Capacity
20 GWAS of Pulmonary function (interaction) (HGVST1454)
Response to antipsychotic therapy, extrapyramidal side effects: abnormal involuntary movement scale (HGVPM820)
  • Antipsychotic Agents
479,554 GWAS of movement-related adverse antipsychotic effects (HGVST461)
Response to antipsychotic therapy, extrapyramidal side effects: Barnes Akathisia rating scale (HGVPM819)
  • Antipsychotic Agents
479,554 GWAS of movement-related adverse antipsychotic effects (HGVST461)
Response to antipsychotic therapy, extrapyramidal side effects: Simpson-Angus scale (HGVPM818)
  • Antipsychotic Agents
479,554 GWAS of movement-related adverse antipsychotic effects (HGVST461)
Rheumatoid arthritis (HGVPM1226)
  • Arthritis, Rheumatoid
4,948 GWAS of rheumatoid arthritis in Koreans (HGVST710)
Rheumatoid arthritis (HGVPM235)
  • Arthritis, Rheumatoid
899,216 GWAS of rheumatoid arthritis in the Spanish population (HGVST185)
Rheumatoid arthritis (DAS28 score wk12 quantitative) (HGVPM10399)
  • Arthritis, Rheumatoid
65,288 GWAS of Rheumatoid arthritis (HGVST4326)
Rheumatoid arthritis (DAS28 score wk6 binary) (HGVPM10397)
  • Arthritis, Rheumatoid
64,124 GWAS of Rheumatoid arthritis (HGVST4326)
Schizophrenia (HGVPM1533)
  • Schizophrenia
1,510,341 GWAS of schizophrenia (HGVST903)
Serum cholesterol (HGVPM568)
  • Cholesterol
959,443 GWAS of serum cholesterol levels in a British population (HGVST312)
sporadic (sCJD) (HGVPM3051)
  • Creutzfeldt-Jakob Syndrome
1,001,571 GWAS of prion diseases (HGVST1013)
Systolic blood presure (HGVPM563)
  • Blood Pressure
959,443 GWAS of systolic blood pressure in a British population (HGVST307)
Tardive dyskinesia (HGVPM1699)
  • Movement Disorders
479,554 GWAS of movement-related adverse antipsychotic effects (HGVST461)
Two-hour glucose challenge (HGVPM769)
  • Blood Glucose
2,401,701 GWAS of glucose levels 2 hours after an oral glucose challenge (HGVST433)
Type II diabetes (HGVPM4)
  • Diabetes Mellitus, Type 2
612,486 GWAS of type II diabetes mellitus (HGVST5)
Type II diabetes (HGVPM5)
  • Diabetes Mellitus, Type 2
772,550 GWAS of type II diabetes mellitus (HGVST3)
Ulcerative colitis (HGVPM1256)
  • Colitis, Ulcerative
1,428,497 GWAS of ulcerative colitis (HGVST730)
variant (vCJD) (HGVPM3052)
  • Creutzfeldt-Jakob Syndrome
511,717 GWAS of prion diseases (HGVST1013)
Visual contrast sensitivity (HGVPM3055)
  • Contrast Sensitivity
642,767 Variants in the 1q21 risk region are associated with a visual endophenotype of autism and schizophrenia (HGVST1611)
Waist-hip ratio (HGVPM1114)
  • Waist-Hip Ratio
2,483,318 Meta-analysis of 32 genome-wide association studies for waist hip ratio adjusted for body mass index (HGVST641)